Linus Amarikwa
Overview
Explore the profile of Linus Amarikwa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hassan M, Mishra K, Amarikwa L, Gupta O, Srivastava S, Scott A, et al.
Ophthalmol Retina
. 2025 Jan;
PMID: 39824306
Purpose: We surveyed vitreoretinal (VR) fellowship program directors (PDs) to elucidate how they assess surgical competency among VR fellows. In addition, we also surveyed fellowship program graduates for the years...
2.
Men C, Amarikwa L, Pham B, Sears C, Clauss K, Lee B, et al.
Ophthalmic Plast Reconstr Surg
. 2025 Jan;
41(1):111-112.
PMID: 39752221
No abstract available.
3.
Ugradar S, Parunakian E, Malkhasyan E, Raika P, Tolentino J, Kossler A, et al.
Graefes Arch Clin Exp Ophthalmol
. 2024 Aug;
263(1):225-230.
PMID: 39136754
Background: Teprotumumab, a novel IGF-1R antibody was recently shown to significantly reduce the signs of acute and chronic thyroid eye disease (TED) related to hyperthyroidism. Given the lower incidence of...
4.
5.
Shah S, Amarikwa L, Sears C, Clauss K, Rajjoub R, Kang J, et al.
Ophthalmology
. 2024 Feb;
131(6):e27-e28.
PMID: 38349298
No abstract available.
6.
Men C, Amarikwa L, Pham B, Sears C, Clauss K, Lee B, et al.
Ophthalmic Plast Reconstr Surg
. 2023 Nov;
40(3):276-285.
PMID: 37972960
Purpose: Teprotumumab, an insulin-like growth factor 1 receptor monoclonal antibody, is FDA-approved to treat thyroid eye disease (TED). The initial clinical trials excluded patients with previous orbital irradiation, surgery, glucocorticoid...
7.
Shah S, Amarikwa L, Sears C, Clauss K, Rajjoub R, Kang J, et al.
Ophthalmology
. 2023 Oct;
131(4):458-467.
PMID: 37852417
Purpose: To assess the duration, incidence, reversibility, and severity of adverse events (AEs) in patients with thyroid eye disease (TED) treated with teprotumumab. Design: Multicenter, retrospective, observational cohort study. Participants:...
8.
Lu T, Amarikwa L, Winn B, Inserra M, Dosiou C, Kossler A
Case Rep Ophthalmol
. 2023 Apr;
14(1):134-139.
PMID: 37034380
Teprotumumab is a novel insulin-like growth factor-1 receptor inhibitor approved for the treatment of thyroid eye disease, but growing reports of hearing loss require further investigation. To date, an effective...
9.
Amarikwa L, Mohamed A, Kim S, Kossler A, Dosiou C
J Clin Endocrinol Metab
. 2022 Oct;
108(4):858-864.
PMID: 36300333
Context: Graves orbitopathy (GO) or thyroid eye disease is a potentially sight-threatening and disfiguring autoimmune disease. Teprotumumab is a monoclonal antibody against the insulin-like growth factor-I receptor that was recently...
10.
Amarikwa L, Michalak S, Caul S, Mruthyunjaya P, Rahimy E
Ophthalmic Surg Lasers Imaging Retina
. 2022 Jul;
53(7):410-411.
PMID: 35858231
Vuity (pilocarpine HCL ophthalmic 1.25%) was approved for the treatment of presbyopia in October 2021. Previous case series have reported the presence of vitreofoveal traction and retinal detachment following pilocarpine...